AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 132 min read$ORKA

Agarwal Arjun sold $846K of ORKA

Agarwal Arjun (Senior Vice President, Finance) sold 9,999 shares of Oruka Therapeutics, Inc. (ORKA) at an average of $84.63 ($83.07–$85.63, $0.85M total) across 4 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Agarwal Arjun
Published Jul 13, 2026, 9:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 13, 2026, 9:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ORKA
Neutral
high confidence
Mentioned
$ORKA
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ORKANeutralLow
01

Why it matters

The newest fact is the specific open-market sale size, price range, and post-transaction holdings by a finance officer under a 10b5-1 plan. This can influence short-term sentiment but does not provide new fundamentals.

02

Market read

Traders may monitor ORKA for sentiment effects from insider activity, but the 10b5-1 framing reduces interpretive weight.

03

What to watch

The filing does not disclose reasons for the sale, and it does not indicate whether other insiders are buying or whether the company has concurrent catalysts (trials, approvals, financing).

Relevance 4/10Novelty 3/10Timing: Filed on 2026-07-13, same day as the reported sale trades.

Background

The article is a SEC Form 4 insider transaction disclosure for Oruka Therapeutics, Inc. (ORKA).

Company-level read

Ticker impact

$ORKANeutralHigh confidence
Context

Oruka Therapeutics (ORKA) disclosed an officer open-market sale by SVP Finance Agarwal Arjun of 9,999 shares for about $846K under a 10b5-1 plan.

Expected impact

Low near-term impact; any reaction is likely limited to sentiment and liquidity rather than fundamentals.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, and it provides no new company performance, guidance, or deal information.

Market effects

Sector

Minimal. Insider selling in a single biotech does not, by itself, reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • issuer
    Oruka Therapeutics, Inc.

    Subject of the Form 4 insider transaction disclosure (ORKA).

  • insider
    Agarwal Arjun

    Senior Vice President, Finance who sold 9,999 shares on 2026-07-13 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ORKA insider trading history →

Related articles

OCT 1
$ORKAMedAI 8/10

How Investors Are Reacting To Oruka Therapeutics (ORKA) Positive Psoriasis Trial Results

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A Phase 2a trial for ORKA-001 in treating moderate-to-severe plaque psoriasis. The drug showed high PASI 90 and PASI 100 response rates, maintained IGA 0/1 responses, and had a safety profile consistent with the IL-23p19 class. The company has no revenue, reported a net loss of $109.688m, and relies on clinical trials and funding. The stock is up sharply over the past year but down 10.2% over the last month.

simplywall.st2 min
SEP 23
$ORKAMedAI 8/10

Why is Oruka Therapeutics stock sliding today?

Oruka Therapeutics' stock fell 2.5% in pre-market trading after releasing positive but expected Week 28 trial data, with 71.4% of patients achieving complete skin clearance. The company's Chief Medical Officer highlighted the potential of ORKA-001. A pre-planned insider sale of 10,000 shares and a cautious market backdrop also contributed to the decline. Oruka's Price-to-Sales ratio remains high, reflecting growth expectations. The company plans to share more data in December 2026 and Q4 2026.

investing.com2 min
SEP 23
$ORKAHighAI 9/10

Oruka Therapeutics, Inc.: Oruka Therapeutics Announces Positive Week 28 Data for ORKA-001 from the Ongoing EVERLAST-A Trial Showing Deepening of Responses Without Additional Dosing

Oruka Therapeutics (ORKA) reported positive Week 28 data from its EVERLAST-A trial of ORKA-001, showing PASI 100 and PASI 90 rates increased to 71.4% and 87.3%, respectively, without additional dosing. The drug maintained a favorable safety profile. Full 52-week data is expected in December 2026, with 16-week EVERLAST-B data due in 4Q 2026.

finanznachrichten.de2 min